Tag: Bristol
Bristol Myers: Priority review accepted for Augtyro
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Bristol Myers: Expiration of the HSR period for RayzeBio
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Bristol Myers: 7% decline in EPS in the 4th quarter
(CercleFinance.com) – Bristol Myers Squibb publishes adjusted EPS (non-GAAP) for the last three months of 2023, down 7% to $1.70, for revenues up 1% to just under 11 .5 billion,…
Bristol Myers Squibb benefits from the success of its anemia products
(AOF) – Bristol Myers Squibb is expected to rise in pre-market on Wall Street after forgetting better than expected results for the fourth quarter. The American pharmaceutical group posted adjusted…
Bristol Myers: 2 FDA priority reviews for Breyanzi
(CercleFinance.com) – Bristol Myers Squibb indicates that health authorities have agreed to examine three regulatory applications relating to Breyanzi (lisocabtagene maraleucel): two applications have been accepted by the Food and…
Bristol Myers: positive trial for subcutaneous Opdivo
(CercleFinance.com) – Bristol Myers presented data this weekend from a phase 3 trial evaluating the subcutaneous formulation of Opdivo (nivolumab) versus intravenous (IV) Opdivo in patients with advanced or metastatic…
Bristol Myers: Positive trial for subcutaneous Opdivo
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Bristol Myers: received a positive opinion from the CHMP
(CercleFinance.com) – Bristol Myers Squibb receives a positive opinion from the CHMP for the CAR T cell therapy Abecma (idecabtagene vicleucel) in previous therapeutic lines for multiple myeloma exposed in…
Bristol Myers:presents Opdivo treatment at ASCO GU 2024
(CercleFinance.com) – Bristol Myers Squibb presents transformative research in the treatment of genitourinary cancers at ASCO GU 2024. The group presents the first presentation of results from the phase 3…
Bristol Myers buys Karuna Therapeutics and its schizophrenia treatment for $14 billion
Published on 12/22/2023 at 3:05 p.m. December 22 (Reuters) – Bristol Myers Squibb announced on Friday an agreement to acquire Karuna Therapeutics for $14 billion…
Bristol Myers: Priority review obtained for Opdivo
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Bristol Myers Squibb: FDA to review data
(CercleFinance.com) – Bristol Myers Squibb and 2seventy bio provide update on US FDA review of SBLA for abecca (idecabtagene vicleucel) in earlier lines of treatment for exposed relapsed or refractory…